Apex Healthcare Bhd operates within the Drug stores and proprietary stores sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Apex Healthcare Bhd with three other
drug stores in Asia:
Shanghai No.1 Pharmacy Co Ltd
sales of 1.24 billion Chinese Renmimbi [US$178.57 million]
of which 59%
was Pharmaceutical Retail),
(16.13 billion Japanese Yen [US$152.31 million]
of which 57%
was Pharmaceutical segment), and
Sapporo Clinical Laboratory Inc.
based in JAPAN
(17.07 billion Japanese Yen [US$161.10 million]
During the year ended December of 2019, sales at
Apex Healthcare Bhd were 688.79 million Malaysian Ringgits (US$164.15 million).
increase of 5.5%
versus 2018, when the company's sales were 652.66 million Malaysian Ringgits.
This was the fifth consecutive year of sales increases at Apex Healthcare Bhd
(and since 2014, sales have increased a total of 38%).
Sales of Manufacturing and Marketing saw an increase
8.0% in 2019, from
53.03 million Malaysian Ringgits to 57.27 million Malaysian Ringgits.
Not all segments of Apex Healthcare Bhd experienced an increase in sales in 2019:
sales of Corporate fell 10.6% to 8.14 million Malaysian Ringgits.
(However, this segment's sales were only a very small portion of the company's overall sales).